QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
NASDAQ:IMGN

ImmunoGen - IMGN Stock Forecast, Price & News

$5.21
-0.09 (-1.70%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.18
$5.36
50-Day Range
$4.70
$6.31
52-Week Range
$3.10
$7.76
Volume
1.95 million shs
Average Volume
3.48 million shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.13

ImmunoGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
151.9% Upside
$13.13 Price Target
Short Interest
Healthy
7.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.27mentions of ImmunoGen in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.93) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

357th out of 1,027 stocks

Pharmaceutical Preparations Industry

153rd out of 503 stocks

IMGN stock logo

About ImmunoGen (NASDAQ:IMGN) Stock

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Stock News Headlines

Brokerages Set ImmunoGen, Inc. (NASDAQ:IMGN) PT at $13.13
YIKES! 220 Pounds of Graphite in Each EV Battery?
Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
YIKES! 220 Pounds of Graphite in Each EV Battery?
Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.
Should You Buy ImmunoGen (IMGN) Ahead of Earnings?
Form 8-K ImmunoGen, Inc. For: Aug 31 - StreetInsider.com
See More Headlines
Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Company Calendar

Last Earnings
10/29/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/24/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
106
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$13.13
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+151.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-139,300,000.00
Net Margins
-210.33%
Pretax Margin
-210.33%

Debt

Sales & Book Value

Annual Sales
$69.86 million
Book Value
$1.61 per share

Miscellaneous

Free Float
213,378,000
Market Cap
$1.15 billion
Optionable
Optionable
Beta
1.00

Social Links


Key Executives

  • Mr. Mark Joseph EnyedyMr. Mark Joseph Enyedy (Age 58)
    Pres, CEO & Director
    Comp: $1.24M
  • Ms. Susan Altschuller Ph.D. (Age 39)
    Sr. VP & CFO
    Comp: $537.53k
  • Dr. Anna Berkenblit M.D. (Age 52)
    MM.Sc, Sr. VP & Chief Medical Officer
    Comp: $647.28k
  • Ms. Stacy A. Coen (Age 51)
    Sr. VP & Chief Bus. Officer
    Comp: $547.66k
  • Ms. Renee Lentini (Age 44)
    VP of Fin. & Principal Accounting Officer
  • Ms. Courtney O'Konek
    Sr. Director of Corp. Communications & Investor Relations
  • Mr. Daniel S. Char J.D. (Age 61)
    Sr. VP & Chief Legal Officer
  • Ms. Audrey Bergan
    Sr. VP & Chief HR Officer
  • Dr. Theresa G. Wingrove (Age 64)
    Sr. VP of Regulatory Affairs & Quality
  • Dr. Mary Margaret Huizinga FACP (Age 44)
    M.D., M.P.H., Sr. VP & Head of Medical Affairs













IMGN Stock - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings
or view top-rated stocks.

What is ImmunoGen's stock price forecast for 2023?

6 brokers have issued twelve-month target prices for ImmunoGen's shares. Their IMGN share price forecasts range from $5.00 to $22.00. On average, they predict the company's stock price to reach $13.13 in the next twelve months. This suggests a possible upside of 149.1% from the stock's current price.
View analysts price targets for IMGN
or view top-rated stocks among Wall Street analysts.

How have IMGN shares performed in 2022?

ImmunoGen's stock was trading at $7.42 at the beginning of the year. Since then, IMGN stock has decreased by 29.0% and is now trading at $5.27.
View the best growth stocks for 2022 here
.

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our IMGN earnings forecast
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its earnings results on Friday, October, 29th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company had revenue of $9.20 million for the quarter, compared to the consensus estimate of $19.03 million. ImmunoGen had a negative trailing twelve-month return on equity of 75.89% and a negative net margin of 210.33%. The firm's revenue was down 49.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.13) EPS.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2022 earnings guidance on Friday, November, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$90.00 million, compared to the consensus revenue estimate of $80.22 million.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.90%), Vanguard Group Inc. (7.08%), State Street Corp (6.61%), Jennison Associates LLC (2.81%), Two Sigma Advisers LP (1.36%) and Dimensional Fund Advisors LP (1.15%). Insiders that own company stock include Craig Barrows, David G Foster, Mark J Enyedy and Thomas Ryll.
View institutional ownership trends
.

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $5.27.

How much money does ImmunoGen make?

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $1.16 billion and generates $69.86 million in revenue each year. The biotechnology company earns $-139,300,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does ImmunoGen have?

The company employs 106 workers across the globe.

Does ImmunoGen have any subsidiaries?
The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More
How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.

This page (NASDAQ:IMGN) was last updated on 12/7/2022 by MarketBeat.com Staff